• English
  • Singapore(USD $)

No relevant currency found


/ /

Clinical Study of Shensong Yangxin Capsule Combined Bisoprolol on Elderly Paroxysmal Atrial Fibrillation

Apr 20,2023 | YILING

6258(2020)04-0688-04 Clinical study of Shensong Yangxin Capsule combined bisoprolol on elderly       paroxysmal atrial fibrillation                                                                                                 LIU Yan1, MIAO Li2, SUN Guangwei3*                                                                                                                                                                                                                                                               (1. Department ofCardiology,  The No. 988 Hospital ofJoint Logistic Support Force, Zhengzhou 450007, China; 2. Department ofCardiology and Nephrology,  Henan General Hospital ofArmed Police, Zhengzhou 450052, China; 3. Chinese Traditional Medicine InstituteofJilin Province, Changchun 130021, China)

Abstract : Objective To investigate the clinical efficacy of Shensong Yangxin Capsule combined with Bisoprolol on elderly paroxysmal atrial fibrillation. Methods A total of 76 patients diagnosed with elderly paroxysmal atrial fibrillation were randomly divided into control group and experimental group, 38 cases in each group. The patients of control group received Bisoprolol only (5 mg/tablet, the average dosage is 8.25±2.12 mg/day); while the patients of experimental group received Shensong Yangxin Capsule (0.4 g/capsule, 4 capsules each time, 3 times a day) combined with bisoprolol (the average dosage is 8.44±2.58 mg/day). The course was 3 months, there were 2 courses. At the end of each course, the patients had been told back to the hospital to be observed the changes of clinical symptoms and determined left atrial diameter and N-terminal pro-brain natriuretic peptide (NT-proBNP) in plasma at 3 months and 6 months after the treatment. Results After treatment of 3 months and 6 months, left atrial diameter of both groups were significantly improved, and NT-proBNP in plasma were decreased (P<0.05). The total effective rate of patients in the experimental group was significantly higher than that in the control group, which were [78.9% (30/38) vs. 57.9% (22/38)] and [81.6% (31/38) vs. 60.5% (23/38)] after 3 and 6 months of treatment respectively. The NT-proBNP level in plasma ofthe experimental group was more significantly decreased than that ofthe control group, which were [133.31±21.54 vs. 198.22±30.34 (3 months)] and [126.39±21.79 vs. 203.31±32.25 (6 months)]. After 6 months of treatment, the improvement of the left atrium diameter in the experimental group was more obvious than that in the control group (32.22±2.79 vs. 37.64±3.26) (all P<0.05). Conclusion Shensong Yangxin Capsule combined with bisoprolol have significant clinical e★cacy on paroxysmal atrial fibrillation in the elderly, which can improve the left atrial diameter ofpatients and reduce the NT-proBNP level in plasma, and it is more obvious than treatment with bisoprolol solely.

Keywords: Shensong Yangxin Capsule; bisoprolol; elderly paroxysmal atrial fibrillation; NT-proBNP